PE20061077A1 - Composicion farmaceutica que comprende 7-terbutoxi-imino-metil-camptotecina - Google Patents
Composicion farmaceutica que comprende 7-terbutoxi-imino-metil-camptotecinaInfo
- Publication number
- PE20061077A1 PE20061077A1 PE2005001353A PE2005001353A PE20061077A1 PE 20061077 A1 PE20061077 A1 PE 20061077A1 PE 2005001353 A PE2005001353 A PE 2005001353A PE 2005001353 A PE2005001353 A PE 2005001353A PE 20061077 A1 PE20061077 A1 PE 20061077A1
- Authority
- PE
- Peru
- Prior art keywords
- composition
- weight
- terbutoxi
- camptotechin
- imino
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 abstract 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 abstract 3
- LZCLXQDLBQLTDK-UHFFFAOYSA-N ethyl 2-hydroxypropanoate Chemical compound CCOC(=O)C(C)O LZCLXQDLBQLTDK-UHFFFAOYSA-N 0.000 abstract 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 abstract 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 abstract 1
- 239000002202 Polyethylene glycol Substances 0.000 abstract 1
- 239000000654 additive Substances 0.000 abstract 1
- 239000004599 antimicrobial Substances 0.000 abstract 1
- 239000003963 antioxidant agent Substances 0.000 abstract 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical compound CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000006184 cosolvent Substances 0.000 abstract 1
- 235000019961 diglycerides of fatty acid Nutrition 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229940116333 ethyl lactate Drugs 0.000 abstract 1
- 235000019960 monoglycerides of fatty acid Nutrition 0.000 abstract 1
- 229920001223 polyethylene glycol Polymers 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 abstract 1
- 239000004094 surface-active agent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: A) UN PRINCIPIO ACTIVO TAL COMO 7-TERBUTOXI-IMINO-METIL-CAMPTOTECINA EN UNA CANTIDAD COMPRENDIDA ENTRE 0.05% A 20% EN PESO DE LA COMPOSICION; B) UN AGENTE LIPOFILICO TALES COMO MONOGLICERIDOS Y DIGLICERIDOS DE ACIDOS GRASOS DE 8 A 10 ATOMOS DE CARBONO, CITRATO DE TRIETILO, ENTRE OTROS; EN UNA CANTIDAD COMPRENDIDA ENTRE 5% A 85% EN PESO DE LA COMPOSICION; C) UN TENSOACTIVO A BASE DE ACEITE DE RICINO HIDROGENADO CON POLIETILENGLICOL EN UNA CANTIDAD COMPRENDIDA ENTRE 5% A 90% EN PESO DE LA COMPOSICION; D) UN COMPONENTE HIDROFILICO TALES COMO PROPILENGLICOL, PEG 400, LACTATO DE ETILO, ENTRE OTROS, EN UNA CANTIDAD COMPRENDIDA ENTRE 5% A 60% EN PESO DE LA COMPOSICION; E) UN COSOLVENTE EN UNA CANTIDAD COMPRENDIDA ENTRE 0 A 20% EN PESO DE LA COMPOSICION Y F) UNO O MAS ADITIVOS TALES COMO ANTIOXIDANTES, AGENTES ANTIMICROBIANOS, ESTABILIZANTES, ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCESO DE PREPARACION. DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO DE ENFERMEDADES PROLIFERATIVAS TAL COMO EL CANCER
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62975704P | 2004-11-19 | 2004-11-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20061077A1 true PE20061077A1 (es) | 2006-11-13 |
Family
ID=35691476
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2005001353A PE20061077A1 (es) | 2004-11-19 | 2005-11-17 | Composicion farmaceutica que comprende 7-terbutoxi-imino-metil-camptotecina |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US8518961B2 (es) |
| EP (1) | EP1814520B1 (es) |
| JP (1) | JP4982378B2 (es) |
| KR (1) | KR101283840B1 (es) |
| CN (1) | CN101056619A (es) |
| AR (1) | AR052033A1 (es) |
| AU (1) | AU2005306018B2 (es) |
| BR (1) | BRPI0518448A2 (es) |
| CA (1) | CA2584343C (es) |
| DK (1) | DK1814520T3 (es) |
| ES (1) | ES2572133T3 (es) |
| GT (1) | GT200500310A (es) |
| HR (1) | HRP20160446T1 (es) |
| HU (1) | HUE027135T2 (es) |
| IL (1) | IL182703A (es) |
| MA (1) | MA29076B1 (es) |
| MX (1) | MX2007005897A (es) |
| MY (1) | MY148647A (es) |
| NO (1) | NO342592B1 (es) |
| NZ (1) | NZ554551A (es) |
| PE (1) | PE20061077A1 (es) |
| PL (1) | PL1814520T3 (es) |
| RU (3) | RU2007122470A (es) |
| SI (1) | SI1814520T1 (es) |
| TN (1) | TNSN07193A1 (es) |
| TW (1) | TWI368521B (es) |
| WO (1) | WO2006053755A1 (es) |
| ZA (1) | ZA200703148B (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GT200500310A (es) | 2004-11-19 | 2006-06-19 | Compuestos organicos | |
| SA06270147B1 (ar) | 2005-06-09 | 2009-12-22 | نوفارتيس ايه جي | عملية لتخليق 5-(مثيل–1h–إيميدازول–1-يل )–3-(ثلاثي فلـورو مثيل)–بنزامـين |
| ITRM20050418A1 (it) * | 2005-08-04 | 2007-02-05 | Sigma Tau Ind Farmaceuti | Sistemi terapeutici a rilascio immediato per il migliorato assorbimento orale di 7-[(e)-t-butilossimminometil] camptotecina. |
| JP2009504616A (ja) * | 2005-08-10 | 2009-02-05 | ノバルティス アクチエンゲゼルシャフト | トポイソメラーゼＩ阻害剤、７−ｔｅｒｔ−ブトキシイミノメチルカンプトテシンの微粒子組成物 |
| WO2008055146A2 (en) * | 2006-10-31 | 2008-05-08 | Wyeth | Formulations of phospholipase enzyme inhibitors |
| US20100070052A1 (en) * | 2008-08-19 | 2010-03-18 | Robb Fujioka | System and method for providing applications and peripherals to a fixed price component-based computing platform |
| MX340819B (es) | 2010-06-29 | 2016-07-26 | Poniard Pharmaceuticals Inc * | Formulacion oral de inhibidores de quinasa. |
| EP2588476A4 (en) | 2010-06-30 | 2014-07-23 | Verastem Inc | SYNTHESIS AND USE OF KINASE INHIBITORS |
| US12226412B2 (en) | 2012-05-25 | 2025-02-18 | Corcept Therapeutics, Inc. | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| US8859774B2 (en) | 2012-05-25 | 2014-10-14 | Corcept Therapeutics, Inc. | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| MX2021007322A (es) * | 2018-12-19 | 2021-07-07 | Corcept Therapeutics Inc | Formulaciones farmaceuticas que contienen relacorilant, un compuesto de azadecalina fusionado con heteroaril-cetona. |
| CA3229030A1 (en) * | 2021-09-05 | 2023-03-09 | Yi-Wen Chu | Formulations with enhanced sn-38 solubility and oral absorption |
| EP4577191A1 (en) * | 2022-08-24 | 2025-07-02 | Lyotropic Delivery Systems Ltd. | Oral delivery of active compounds for treating glycogen storage diseases |
| AU2023355849A1 (en) | 2022-10-06 | 2025-04-03 | Corcept Therapeutics Incorporated | Formulations of glucocorticoid receptor modulators |
| IL320512A (en) | 2022-10-28 | 2025-06-01 | Corcept Therapeutics Inc | Amyotrophic lateral sclerosis treatments using desocorilant |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9113872D0 (en) | 1991-06-27 | 1991-08-14 | Sandoz Ag | Improvements in or relating to organic compounds |
| JPH08504811A (ja) | 1992-12-24 | 1996-05-28 | ヘマジェン／ピーエフシー | フルオロカーボンのエマルジョン |
| TW406020B (en) | 1993-09-29 | 2000-09-21 | Bristol Myers Squibb Co | Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent |
| US5597829A (en) * | 1994-05-09 | 1997-01-28 | Bionumerik Pharmaceuticals, Inc. | Lactone stable formulation of camptothecin and methods for uses thereof |
| US5726181A (en) * | 1995-06-05 | 1998-03-10 | Bionumerik Pharmaceuticals, Inc. | Formulations and compositions of poorly water soluble camptothecin derivatives |
| US6458373B1 (en) | 1997-01-07 | 2002-10-01 | Sonus Pharmaceuticals, Inc. | Emulsion vehicle for poorly soluble drugs |
| DK0999826T3 (da) | 1997-07-29 | 2004-07-26 | Upjohn Co | Selv-emulgerende formulering til lipofile forbindelser |
| AR013261A1 (es) | 1997-08-01 | 2000-12-13 | Smithkline Beecham Corp | Formulaciones farmaceuticas para analogos de camptotecina en capsula de gelatina |
| EP1075252A2 (en) | 1998-05-07 | 2001-02-14 | ELAN CORPORATION, Plc | Solvent/cosolvent free microemulsion and emulsion preconcentrate drug delivery systems |
| US20030059465A1 (en) | 1998-05-11 | 2003-03-27 | Unger Evan C. | Stabilized nanoparticle formulations of camptotheca derivatives |
| GB9903547D0 (en) | 1999-02-16 | 1999-04-07 | Novartis Ag | Organic compounds |
| DE69901379T2 (de) * | 1999-03-09 | 2002-11-07 | Istituto Nazionale Per Lo Studio E La Cura Dei Tumori, Mailand/Milano | Camptothecin-Derivate mit Antitumor-Wirkung |
| IT1306129B1 (it) * | 1999-04-13 | 2001-05-30 | Sigma Tau Ind Farmaceuti | Esteri della l-carnitina o di alcanoil l-carnitine utilizzabili comelipidi cationici per l'immissione intracellulare di composti |
| CA2373994A1 (en) | 1999-05-24 | 2000-11-30 | Sonus Pharmaceuticals, Inc. | Emulsion vehicle for poorly soluble drugs |
| GB9918885D0 (en) | 1999-08-10 | 1999-10-13 | Pharmacia & Upjohn Spa | Pharmaceutical formulations in hydroxypropymethycellulose capsules |
| GB9925127D0 (en) | 1999-10-22 | 1999-12-22 | Pharmacia & Upjohn Spa | Oral formulations for anti-tumor compounds |
| US20040009229A1 (en) * | 2000-01-05 | 2004-01-15 | Unger Evan Charles | Stabilized nanoparticle formulations of camptotheca derivatives |
| GB0001928D0 (en) * | 2000-01-27 | 2000-03-22 | Novartis Ag | Organic compounds |
| US20020150615A1 (en) * | 2001-02-12 | 2002-10-17 | Howard Sands | Injectable pharmaceutical composition comprising microdroplets of a camptothecin |
| US6653319B1 (en) * | 2001-08-10 | 2003-11-25 | University Of Kentucky Research Foundation | Pharmaceutical formulation for poorly water soluble camptothecin analogues |
| JP2005508354A (ja) | 2001-10-15 | 2005-03-31 | クリチテック インコーポレーテッド | 水に溶けにくい薬物の送込み用組成物および方法並びに治療方法 |
| US20060078618A1 (en) | 2001-12-11 | 2006-04-13 | Constantinides Panayiotis P | Lipid particles and suspensions and uses thereof |
| JP2003267891A (ja) | 2002-03-13 | 2003-09-25 | Mitsubishi-Kagaku Foods Corp | Ｗ／ｏ／ｗ型エマルション製剤 |
| CZ294371B6 (cs) * | 2002-06-10 | 2004-12-15 | Pliva - Lachema, A. S. | Stabilizovaná farmaceutická kompozice na bázi polyoxyethylovaného ricinového oleje a způsob její přípravy |
| EP1393719A1 (en) | 2002-08-23 | 2004-03-03 | Munich Biotech AG | Camptothecin-carboxylate formulations |
| JP4426749B2 (ja) | 2002-07-11 | 2010-03-03 | 株式会社産学連携機構九州 | Ｏ／ｗ型エマルション製剤 |
| US20040171560A1 (en) * | 2002-12-23 | 2004-09-02 | Dabur Research Foundation | Stabilized pharmaceutical composition |
| JP2006199590A (ja) * | 2003-09-04 | 2006-08-03 | Nano Career Kk | 水溶性の塩基性薬物内包ナノ粒子含有組成物 |
| KR20060110872A (ko) * | 2003-10-29 | 2006-10-25 | 소너스파머슈티칼즈인코포레이티드 | 토코페롤 변성 치료제 약물 화합물 |
| EP1706098A4 (en) * | 2003-11-26 | 2012-08-15 | Supernus Pharmaceuticals Inc | MICELLAR SYSTEMS SUITABLE FOR THE DELIVERY OF LIPOPHILIC OR HYDROPHOBIC COMPOUNDS |
| WO2005060871A1 (en) | 2003-12-17 | 2005-07-07 | Bionumerik Pharmaceuticals, Inc. | Pharmaceutical formulations of camptothecins and process for making same |
| GT200500310A (es) | 2004-11-19 | 2006-06-19 | Compuestos organicos |
-
2005
- 2005-10-28 GT GT200500310A patent/GT200500310A/es unknown
- 2005-11-17 HU HUE05807851A patent/HUE027135T2/en unknown
- 2005-11-17 ES ES05807851T patent/ES2572133T3/es not_active Expired - Lifetime
- 2005-11-17 AU AU2005306018A patent/AU2005306018B2/en not_active Ceased
- 2005-11-17 CA CA2584343A patent/CA2584343C/en not_active Expired - Fee Related
- 2005-11-17 PE PE2005001353A patent/PE20061077A1/es not_active Application Discontinuation
- 2005-11-17 WO PCT/EP2005/012334 patent/WO2006053755A1/en not_active Ceased
- 2005-11-17 PL PL05807851T patent/PL1814520T3/pl unknown
- 2005-11-17 HR HRP20160446TT patent/HRP20160446T1/hr unknown
- 2005-11-17 CN CNA2005800391358A patent/CN101056619A/zh active Pending
- 2005-11-17 AR ARP050104840A patent/AR052033A1/es unknown
- 2005-11-17 BR BRPI0518448-7A patent/BRPI0518448A2/pt not_active Application Discontinuation
- 2005-11-17 MX MX2007005897A patent/MX2007005897A/es active IP Right Grant
- 2005-11-17 KR KR1020077011327A patent/KR101283840B1/ko not_active Expired - Fee Related
- 2005-11-17 SI SI200532062A patent/SI1814520T1/sl unknown
- 2005-11-17 US US11/718,275 patent/US8518961B2/en not_active Expired - Fee Related
- 2005-11-17 JP JP2007541793A patent/JP4982378B2/ja not_active Expired - Fee Related
- 2005-11-17 MY MYPI20055374A patent/MY148647A/en unknown
- 2005-11-17 RU RU2007122470/15A patent/RU2007122470A/ru unknown
- 2005-11-17 DK DK05807851.0T patent/DK1814520T3/en active
- 2005-11-17 EP EP05807851.0A patent/EP1814520B1/en not_active Expired - Lifetime
- 2005-11-17 NZ NZ554551A patent/NZ554551A/en not_active IP Right Cessation
- 2005-11-18 TW TW094140699A patent/TWI368521B/zh not_active IP Right Cessation
-
2007
- 2007-04-17 ZA ZA200703148A patent/ZA200703148B/xx unknown
- 2007-04-19 IL IL182703A patent/IL182703A/en active IP Right Grant
- 2007-05-02 NO NO20072258A patent/NO342592B1/no not_active IP Right Cessation
- 2007-05-18 TN TNP2007000193A patent/TNSN07193A1/fr unknown
- 2007-05-22 MA MA29925A patent/MA29076B1/fr unknown
-
2012
- 2012-05-17 RU RU2012120388A patent/RU2620331C2/ru not_active IP Right Cessation
-
2015
- 2015-07-30 RU RU2015131700A patent/RU2015131700A/ru not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20061077A1 (es) | Composicion farmaceutica que comprende 7-terbutoxi-imino-metil-camptotecina | |
| ES2524320T3 (es) | Composición para la prevención o el tratamiento de enfermedad asociada con trombo o émbolo | |
| PE20060464A1 (es) | Composicion farmaceutica que comprende flibanserina para el tratamiento de trastornos sexuales | |
| CY1120888T1 (el) | Διαδερμικες φαρμακευτικες συνθεσεις περιλαμβανοντας ενεργους παραγοντες | |
| AR073123A1 (es) | Composicion farmaceutica que comprende un taxano sustancialmente amorfo para utilizarse en el tratamiento de la enfermedad neoplasica | |
| AR052545A1 (es) | Suspension no acuosa inyectable | |
| SV2008003071A (es) | Composiciones farmaceuticas de antagonistas del anticuerpo anti-cd40 | |
| HRP20220361T1 (hr) | Postupak i sastav za liječenje očne hipertenzije i glaukoma | |
| PE20130216A1 (es) | Formulacion topica para un inhibidor de jak | |
| PE20151425A1 (es) | Formulaciones farmaceuticas muy concentradas que comprenden un anticuerpo anti-cd20 | |
| EA201170413A1 (ru) | Составы с замедленным высвобождением, полученные с применением неводных носителей | |
| CO6311006A2 (es) | Composicion farmaceutica que comprende un agente que activa las celulas t regulatorias cd4+cd25+ efectiva a dosis altas | |
| HUP0301405A2 (hu) | Fokozott oldékonyságú gyógyhatású komponenseket tartalmazó készítmények | |
| CO2021000174A2 (es) | Composiciones tópicas para el alivio del dolor | |
| MX349176B (es) | Suministro transdermico de farmaco empleando un osmolito y un agente vasoactivo. | |
| BR112015020707A2 (pt) | formulações transdermicas | |
| MX2024000828A (es) | Formulaciones de parasiticida de isoxazolina y metodos para el tratamiento de la blefaritis. | |
| MX393613B (es) | Composiciones de gel para administracion transdermica para maximizar las concentraciones de farmaco en el estrato corneo y suero, y metodos de uso de las mismas. | |
| MX2021016055A (es) | Formulaciones y métodos de parasiticidas de isoxazolina para el tratamiento de la blefaritis. | |
| PE20090387A1 (es) | Formulacion de pasireotida | |
| BRPI0418070A (pt) | composição para cuidados pessoais, uso de uma uréia substituìda e método para reduzir a degradação da cor de uma composição para cuidados pessoais | |
| ES2614481T3 (es) | Composición para la administración de principios activos mediante dispositivos de implante | |
| AR061269A1 (es) | Composicion y metodo de revascularizacion para el tratamiento de enfermedades isquemicas usando eritropoyetina | |
| CR20180014A (es) | Composiciones de matriz polimérica tópicas que comprenden una alta concentración de hialuronato de sodio bio-fermentado y sus usos | |
| MX2022013275A (es) | Composicion conservadora/de cuidado personal sinergica con ester de poliglicerol. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal | ||
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |